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Pathophysiology of Hemostasis
Blood loss from injured vessels is prevented by hemostasis, a
complex process that is tightly regulated by thrombin gener-
ation and ﬁbrin deposition (also called coagulation), platelet–
vessel wall interaction (primary hemostasis), and ﬁbrin dis-
solution (ﬁbrinolysis). Perturbation of any of these processes
may result in hemorrhage or thrombosis.
Thrombin Generation and Fibrin Deposition
(Coagulation)
Thrombin generation and ﬁbrin deposition (coagulation) is a
tightly regulated process driven by procoagulant factors
(from XII down to ﬁbrinogen) that are counterbalanced by
anticoagulant factors (e.g., antithrombin, protein C, protein S,
and the tissue factor pathway inhibitor). The balance between
pro- and anticoagulants prevents unwanted thrombin gener-
ation and ﬁbrin deposition under physiological conditions. In
contrast, perturbation of the balance that favors the procoa-
gulants or the anticoagulants may lead to thrombosis or
hemorrhage, respectively.
Platelet–Vessel Wall Interaction (Primary Hemostasis)
Platelets play a dual role in hemostasis.
First, they adhere to the subendothelium at the site of a
vessel wall injury and form an aggregate of one another.
Adhesion and aggregation are mediated by the adhesive
multimeric protein von Willebrand factor (VWF), which in
turn is regulated by ADAMTS13 (a disintegrin and metal-
loproteinase with a thrombospondin type 1 motif, member
13) that reduces its multimeric size and therefore platelet
adhesiveness and aggregation. Defective platelet function (e.
g., thrombocytopenia/thrombocytopathy) or VWF deﬁciency
may result in hemorrhage, whereas increased platelet func-
tion (e.g., platelet hyperactivity, increased levels of VWF, or
ADAMTS13 deﬁciency) may result in thrombosis.
Second, platelets support thrombin generation byassembling
on their surface vitamin-K-dependent coagulation factors, a
function known as platelet procoagulant activity. Defective
platelet procoagulant activity may result in hemorrhage.
Fibrin Dissolution (Fibrinolysis)
Fibrinolysis is the system responsible for ﬁbrin degradation
that operates through two opposing drivers regulating the
conversion of plasminogen (precursor) to plasmin (active
enzyme) that ultimately digests ﬁbrin. The proﬁbrinolytic
drivers include the tissue plasminogen activator (tPA), factor
XIIa, and the urokinase plasminogen activator. The antiﬁbri-
nolytic drivers include the thrombin-activatable ﬁbrinolysis
inhibitor (TAFI), the inhibitor to tPA (PAI), and the plasmin
inhibitor. Under physiological conditions, the balance be-
tween the two opposing drivers prevents unwanted plasmin
generation. Conversely, hypo- or hyperﬁbrinolysis may result
in thrombosis or hemorrhage, respectively.
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Abstract Acute and chronic liver diseases have long been considered prototypes of acquired
hemorrhagic diseases. Over the last decade, evidence stemming from the laboratory
bench and clinical practice has indicated that hemostasis abnormalities, until recently
considered as the cause of bleeding in these conditions, are rebalanced to normal
despite the abnormal results of the hemostasis tests such as prothrombin time and
platelet counts. Consequently, the commonly used therapeutic approach—the infusion
of plasma, platelets, or other prohemostatic agents—are not biologically plausible and
should be reconsidered. In this article, the author reviews the evidence supporting the
changing paradigm.
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Derangement of the above mechanisms has been reported
to occur in liver disease. Here I will brieﬂy review the
hemostasis abnormalities in acute and chronic liver disease
(►Table 1).
Acute Liver Disease
Acute liver disease (ALD) is a condition characterized by a
sudden and severe deﬁciency of coagulation factors (both
pro- and anticoagulants),1 thrombocytopenia, and systemic
inﬂammation.2 Notably, the only coagulation factors that are
not decreased (they are actually increased) are VWFand FVIII.
They are probably increased because they are not synthesized
by hepatocytes, but by endothelial cells.
Thrombin Generation and Fibrin Deposition
(Coagulation) in Acute Liver Disease
Although hemorrhage in patients with ALD is not frequently
observed, the condition has been considered for some time as
a hemorrhagic disease because the prothrombin time (PT) in
this setting is abnormally prolonged. Consequently, PT has
been used as a prognostic index (PT prolongation is part of the
deﬁnition of ALD3), but also as an index to guide transfusion
(prophylaxis or rescue therapy) on the belief that correction
of the PT would result in the clinical efﬁcacy of fresh frozen
plasma (FFP) or other prohemostatic agents. Recently, labo-
ratory studies have shown that coagulation in patients with
ALD is “rebalanced” despite PT prolongation. Thrombin-gen-
eration tests performed in platelet-poor plasma in the pres-
ence of exogenously added thrombomodulin showed that
patients with ALD generate as much thrombin as healthy
subjects.4,5 This was due to the commensurate deﬁciency of
both pro- and anticoagulant factors, a typical feature of ALD.
Hence, PT cannot be taken as a reliable index of hemorrhagic
risk and cannot be used to guide transfusion using FFP or
other prohemostatic agents. Prothrombin time, though sen-
sitive to a deﬁciency of procoagulant factors (VII, X, II, and
ﬁbrinogen), is not sensitive to a deﬁciency of anticoagulant
factors, which are concomitantly decreased in patients with
liver disease.6 In fact, PT, when prolonged, can be used to
diagnose patients with a congenital deﬁciency of procoagu-
lants, but not to diagnose patients with a congenital deﬁcien-
cyof anticoagulants. The PT iswithin normal limits in patients
with a congenital deﬁciency of naturally occurring antico-
agulants—antithrombin, protein C, or protein S—a condition
where the PT should be shortened because these patients
generate greater amounts of thrombin than normal subjects.
Prothrombin time displays different sensitivity toward pro-
and anticoagulants because upon triggering coagulation in
vitro, procoagulants act quickly and limit thrombin genera-
tion and ﬁbrin formation (i.e., the PT endpoint), whereas
anticoagulants act at a much slower rate.6 For example,
protein C, one of themost powerful anticoagulants, circulates
in plasma as a zymogen and is activated invivo by thrombin in
complex with its endothelial receptor thrombomodulin.7
Neither the reagent nor plasma used to measure the PT
contains sufﬁcient amounts of thrombomodulin. Therefore,
protein C that is markedly decreased in chronic liver disease
(CLD) cannot be optimally activated within the relatively
short time needed for PT execution (few seconds) and cannot
exert its full anticoagulant activity as it occurs in vivo.
Platelet–Vessel Wall Interaction in Acute Liver Disease
Although thrombocytopenia is not (in general) very severe in
patients with ALD, it is observed in this setting. Although the
mechanism has not yet been experimentally investigated, it
can be surmised that the increased levels of VWFand reduced
levels of ADAMTS13 are able to compensate for the mild
thrombocytopenia observed in ALD.8 Hence, thrombocyto-
penia is not a crucial issue in patients with ALD.
Fibrinolysis in Acute Liver Disease
Recent evidence indicates that patients with ALD also have
hypoﬁbrinolysis, which might increase the risk of thrombo-
sis.4 Thrombosis is in fact not an infrequent ﬁnding in patients
with ALD.9 In addition to hypoﬁbrinolysis, another factor that
may trigger thrombosis is the reduced level of protein C
combined with an increased level of FVIII. Furthermore, the
systemic inﬂammatory process that takes place in ALD10may
favor the tissue-factor-dependent activation of coagulation,
Table 1 Hemostasis abnormalities observed in patients with liver disease
Mechanism Abnormality
Acute liver disease Status Chronic liver disease Status
Thrombin generation and ﬁbrin
deposition (coagulation)
Low procoagulants
High factor VIII
Low anticoagulants
High procoagulant
microparticles
Rebalanced Low procoagulants
High factor VIII
Low anticoagulants
Rebalanced
Platelet-vessel wall interaction
(primary hemostasis)
Thrombocytopenia
High VWF
Low ADAMTS13
Rebalanced Thrombocytopenia
High VWF
Low ADAMTS13
Rebalanced
Fibrin dissolution (ﬁbrinolysis) Hypoﬁbrinolysis
(established)
Not rebalanced Hyperﬁbrinolysis
(controversial)
Rebalanced?
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; VFW, von Willebrand factor.
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which may also be triggered by procoagulant micropar-
ticles11 found in patients with ALD.
Recent observations suggest a changing paradigm of the
hemostasis abnormalities associated with ALD. It is not, as
previously believed, a hemorrhagic condition. It should rather
be considered as a condition in which hemostasis is reba-
lanced. Therefore, the practice of infusing FFP or other prohe-
mostatic agents to correct the abnormal hemostasis tests (PTor
platelet counts) should be reconsidered, as it is not biologically
plausible nor there is evidence that it is clinically effective. The
infusion of FFP in particular might (paradoxically) “make a bad
situationworse”because ofﬂuidoverload. The observation of a
rebalanced hemostasis suggests also that patientswithALDare
not “auto-anti–coagulated” as suggested by the prolonged PT
and could therefore beneﬁt from antithrombotic therapy (or
prophylaxis) in the case of thrombosis.
Chronic Liver Disease
Chronic liver disease is characterized by a variable deﬁciency
of coagulation factors (both pro- and anticoagulants). At
variance with ALD, the deﬁciency in CLD is more likely due
to synthetic defects rather than to consumption. As in ALD,
the VWF and FVIII are increased in CLD. Thrombocytopenia is
a distinct feature of CLD, and the platelet counts are in general
smaller than those observed for ALD.
Coagulation in Chronic Liver Disease
Hypocoagulability
There is strong experimental evidence that coagulation
(thrombin and ﬁbrin formation) is rebalanced in CLD. Plate-
let-poor plasma from patients with CLD when tested in the
presence of thrombomodulin generates normal amounts of
thrombin despite the prolonged PT.12 In ALD—as in CLD—
coagulation is rebalanced because of the commensurate
deﬁciency of both pro- and anticoagulants. Therefore, the
PT that is not representative of in vivo coagulation is not a
reliable test of bleeding prediction or as a guide for transfu-
sion therapy (as described previously). Furthermore, the
observation of normal thrombin generation would question
the common practice of treating patients with CLD with an
infusion of FFP or other prohemostatic agents to correct the
prolonged PT before an invasive procedure or as a rescue
therapy in case of bleeding.
Controlled randomized trials have shown that recombi-
nant activated factor VII (rFVIIa), a potent prohemostatic
agent currently licensed for the treatment of patients with
FVIII inhibitors, poorly stops or prevents bleeding in patients
(1) who have bleeding esophageal varices,13–15 or (2) were
undergoing hepatectomy.16,17 Although there are no con-
trolled randomized trials on the efﬁcacy/safety of FFP in
patients with CLD, a recent in vitro study investigated plas-
mas from patients with CLD towhich a normal pooled plasma
was added at a proportion similar to that obtained in vivo
when 15 mL/kg of FFP is infused. Pre- and postaddition
plasmas were analyzed for PT and thrombin generation.
Although the PT was somewhat shortened (though not
completely normalized) at postinfusion, thrombin generation
remained unchanged.18 These in vitro experiments cast
doubt on the efﬁcacy of FFP in this setting. Furthermore,
the indiscriminate infusion of FFP in these patients could
increase portal hypertension, thus (paradoxically) increasing
the risk of bleeding.
Hypercoagulability
When thrombin generation was measured with and without
the addition of thrombomodulin in the plasma of patientswith
CLD, the endogenous thrombin potential (ETP; the main
parameter of a thrombin generation assay) was expressed as
a ratio—with or without thrombomodulin. This ratio was
signiﬁcantly higher in patients than in the controls.19 The
ETP ratio is considered an index of plasma hypercoagulability
(by deﬁnition: the higher the ETP ratio, the greater the
hypercoagulability).20 The ETP ratio in patients with CLD
was directly correlated with the increased levels of FVIII (the
most potent driver of thrombin generation) and inversely
correlated with the decreased levels of protein C (the most
important driver of thrombin inhibition).19 These observations
suggest that patients with CLD possess a procoagulant imbal-
ance stemming from an in vitro resistance to thrombomodulin
that can be explained by the increased levels of FVIII and
decreased levels of protein C that are typical features of
patients with CLD. Whether the in vitro resistance to throm-
bomodulin promotes the increased risk of venous thrombo-
embolism that has been observed in patients with CLD21,22 is
still unknown. Preliminary retrospective observations showed
that patients with CLDwho had high ETP ratios were at higher
risk to develop de novo episodes of portal vein thrombosis.23
The occurrence of hypercoagulability in patientswith CLDmay
have practical implications outside thrombosis aswell. Throm-
bin has been identiﬁed as a possible mediator of the progres-
sion of liver ﬁbrosis in patients with CLD that might be
responsible for parenchymal extinction.24
These study results cast serious doubts on the validity of
infusion of FFP or other prohemostatic agents such as rFVIIa or
prothrombin complex concentrates in patients with CLD.
Furthermore, they also show that patients with CLD are not
auto-anti–coagulated as has been believed; therefore, they
should be treated with anticoagulants to prevent or treat
thrombosis. A recent clinical trial of patients awaiting liver
transplantation showed that antithrombotic prophylaxis with
low-molecular-weight heparin was effective in preventing
portal vein thrombosis without signiﬁcant bleeding events.25
Platelet–Vessel Wall Interaction in Chronic Liver
Disease
There is strong experimental evidence that in addition to
coagulation, primary hemostasis is rebalanced in CLD. Lisman
et al26 showed that platelets from patients with CLD adhere
normally to collagen in an in vitro system operating under
ﬂow conditions. The authors concluded that elevated levels of
VWF observed in these patients compensated for the relative
thrombocytopenia observed in this setting.
As mentioned, platelets support thrombin generation by
exposing on their surface negatively charged phospholipids
Seminars in Liver Disease Vol. 37 No. 1/2017
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that bind vitamin-K-dependent coagulation factors, thus
speeding up thrombin generation. Tripodi et al27 showed
that thrombin generation in platelet-rich plasma from pa-
tients with CLD was similar to that of healthy subjects,
provided that platelet counts were adjusted to a standard
count of 100  109/L.27 The platelet count that generated
thrombin amounts equivalent to the lower limit of the normal
range was 56  109/L.27 The data suggest that platelets from
patients with CLD are qualitatively able to support normal
thrombin generation if patients are not severely thrombocy-
topenic. In line with these observations, the American Asso-
ciation for the Study of the Liver in a recent position paper
recommends correcting platelet counts if they are lower than
50  109/L before liver biopsy.28 A recent study investigated
the effect of a single infusion of an adult platelet unit in
patients with CLD before undergoing invasive procedures
when their baseline platelet counts were < 50  109/L. Post-
infusion platelet counts were marginally increased, but
thrombin generation in platelet-rich plasma or thromboelas-
tography in whole blood remained unchanged.29 These ob-
servations suggest that if platelets are to be increased to an
extent sufﬁcient to modify functional platelet assays, multi-
ple transfusions are required, or alternatively, platelet counts
should be increased by nontransfusional approacheswith the
administration of agonists of the thrombopoietin receptor
such as eltrombopag. This drug has been successfully used to
increase platelet numbers in patients with immune throm-
bocytopenia30 and in patients with hepatitis C virus infection
before antiviral therapy.31 Recently, eltrombopag was admin-
istered to patients with CLD, who were thrombocytopenic
and required invasive procedures.32 The drug was effective in
increasing platelet numbers, but the study was terminated
because of an excessive rate of portal vein thromboses in
patients treated with the drug.32
A decision should be made about a transfusional or non-
transfusional approach in CLD only after careful consideration
of the beneﬁt/risk ratio in individual patients.33
Fibrinolysis in Chronic Liver Disease
Little information is available on ﬁbrinolysis in patients with
CLD. Early studies reported that hyperﬁbrinolysis was asso-
ciated with cirrhosis.34 However, in those studies ﬁbrinolysis
was assessed by measuring pro- or antiﬁbrinolytic param-
eters that (by deﬁnition) cannot account for the balance
between the pro- and antiﬁbrinolytic drivers operating in
vivo. Recent studies have investigated ﬁbrinolysis in patients
with CLD by global assays.35–37 The results have been incon-
sistent: Two studies concluded that patients with CLD possess
hyperﬁbrinolysis, mostly due to the considerable reduction of
TAFI36,37; one study concluded that ﬁbrinolysis is substan-
tially rebalanced because of the parallel reduction of both
pro- and antiﬁbrinolytic drivers.35 It is therefore still unclear
whether hyperﬁbrinolysis exists in patients with CLD and
whether it is responsible for the bleeding events occasionally
observed in these patients. On the other hand, controlled
randomized clinical trials of antiﬁbrinolytic drugs (e.g., tra-
nexamic acid or epsilon aminocaproic acid) for controlling
bleeding in this setting have never been performed.38
Conclusions
Experimental observations and clinical practice show that
hemostasis in ALD and CLD is probably rebalanced by the
commensurate reduction of both pro- and anticoagulants and
by the increased levels of VWF and FVIII. Consequently, both
conditions that were until recently considered as the proto-
types of acquired hemorrhagic diseases should be reconsid-
ered with important practical implications. For instance, the
bleeding events observed in patients with CLD are not due to
hemostasis derangement, but probably to other conditions
that underlie CLD such as portal hypertension, recurrent
bacterial infections, endothelial dysfunction, or hepatorenal
syndrome. These conditions need to be treated and new
therapeutic strategies to control bleeding in patients with
liver disease developed. In addition, although hemostasis is
substantially rebalanced, it is not as stable as in healthy
individuals; therefore, it may cause hemorrhage or thrombo-
sis depending on the circumstantial risk factors. The above
observationsmake liver disease shift frompurely hemorrhag-
ic to a mixed and thrombosis-liable disease.
Abbreviations
ADAMTS13 a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13
ALD acute liver disease
CLD chronic liver disease
ETP endogenous thrombin potential
FFP fresh frozen plasma
FVIII factor VIII
PAI inhibitor to tPA
PT prothrombin time
rFVIIa recombinant activated factor VII
TAFI thrombin-activatable ﬁbrinolysis inhibitor
tPA tissue plasminogen activator
VWF von Willebrand factor.
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